CL2012000991A1 - Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras. - Google Patents

Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras.

Info

Publication number
CL2012000991A1
CL2012000991A1 CL2012000991A CL2012000991A CL2012000991A1 CL 2012000991 A1 CL2012000991 A1 CL 2012000991A1 CL 2012000991 A CL2012000991 A CL 2012000991A CL 2012000991 A CL2012000991 A CL 2012000991A CL 2012000991 A1 CL2012000991 A1 CL 2012000991A1
Authority
CL
Chile
Prior art keywords
sglt
modulators
diabetes
pharmaceutical composition
metabolic syndrome
Prior art date
Application number
CL2012000991A
Other languages
English (en)
Inventor
Mark G Bock
Gregory Raymond Bebernitz
Dumbala Srinivas Reddy
Atul Kashinath Hajare
Vinod Vyavahare
Sandeep Bhausahed Bhosale
Suresh Eknath Kurhade
Videsh Salunkhe
Nadim S Shaikh
Debnath Bhuniya
P Venkata Palle
Lili Feng
Jessica Liang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000991(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012000991A1 publication Critical patent/CL2012000991A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Compuestos derivados de glicósidos, moduladores de SGLT; forma cristalina de l-prolina de (2s,3r, 4r, 5s, 6r)-2-[4-cloro-3-(3,4-dihidro-2h-benzo[1,4]-oxazin-6-il-,eto)-fenil]-6-hidroxi-metil-tetrahidro-piran-3,4.5-triol; composición farmacéutica; producto combinado; y su uso en síndrome metabólico, diabetes, entre otros.
CL2012000991A 2009-10-20 2012-04-19 Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras. CL2012000991A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2173DE2009 2009-10-20
IN2689DE2009 2009-12-23

Publications (1)

Publication Number Publication Date
CL2012000991A1 true CL2012000991A1 (es) 2012-09-07

Family

ID=43216622

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000991A CL2012000991A1 (es) 2009-10-20 2012-04-19 Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras.

Country Status (39)

Country Link
US (7) US8163704B2 (es)
EP (1) EP2491029B1 (es)
JP (2) JP5384744B2 (es)
KR (2) KR20140054415A (es)
CN (1) CN102656165B (es)
AR (1) AR078685A1 (es)
AU (1) AU2010309833B2 (es)
BR (1) BR112012009053B1 (es)
CA (1) CA2777812C (es)
CL (1) CL2012000991A1 (es)
CO (1) CO6531486A2 (es)
CR (1) CR20120176A (es)
CU (1) CU24079B1 (es)
CY (1) CY1117409T1 (es)
DK (1) DK2491029T3 (es)
EA (1) EA023781B1 (es)
EC (1) ECSP12011909A (es)
ES (1) ES2564191T3 (es)
GT (1) GT201200117A (es)
HN (1) HN2012000798A (es)
HR (1) HRP20160436T1 (es)
HU (1) HUE027531T2 (es)
IL (1) IL219309A (es)
JO (1) JO3152B1 (es)
MA (1) MA33737B1 (es)
MX (1) MX2012004700A (es)
MY (1) MY158326A (es)
NZ (1) NZ598717A (es)
PE (1) PE20121281A1 (es)
PH (1) PH12012500518A1 (es)
PL (1) PL2491029T3 (es)
RS (1) RS54563B1 (es)
SG (1) SG179562A1 (es)
SI (1) SI2491029T1 (es)
TN (1) TN2012000109A1 (es)
TW (2) TWI558723B (es)
UY (1) UY32958A (es)
WO (1) WO2011048112A1 (es)
ZA (1) ZA201201680B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3280A (en) 2009-03-23 2015-05-31 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as TRPA1 modulators
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
CN102134226B (zh) * 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
TWI599360B (zh) 2010-05-11 2017-09-21 健生藥品公司 醫藥調配物
RS55056B1 (sr) 2011-04-13 2016-12-30 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
US8614195B2 (en) * 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
KR20140019834A (ko) 2011-04-14 2014-02-17 노파르티스 아게 글리코시드 유도체 및 그의 용도
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
WO2012165914A2 (en) * 2011-06-01 2012-12-06 Green Cross Corporation Novel diphenylmethane derivatives as sglt2 inhibitors
CN102827122B (zh) * 2011-06-17 2015-01-14 山东轩竹医药科技有限公司 糖苷衍生物
CN102863417B (zh) * 2011-07-09 2015-01-14 山东轩竹医药科技有限公司 C-糖苷衍生物
TWI589576B (zh) 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
EP2968258B1 (en) * 2013-03-11 2020-02-12 Janssen Pharmaceutica NV Dual sglt1/sglt2 inhibitors
EP3010586A1 (en) 2013-06-21 2016-04-27 Lupin Limited Substituted heterocyclic compounds as crac modulators
US9790231B2 (en) 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
CN104250272B (zh) * 2013-06-27 2018-10-09 上海方楠生物科技有限公司 一种利用微反应器制备列净类药物中间体的方法
CN107311992B (zh) * 2013-09-09 2020-08-18 上海研健新药研发有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
AR098670A1 (es) 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
CN105294624B (zh) * 2015-11-16 2018-01-12 山东罗欣药业集团股份有限公司 一种达格列净的制备方法
MX392177B (es) 2016-06-17 2025-03-19 Daewoong Pharmaceutical Co Ltd Metodo para producir derivado de difenilmetano
WO2018089449A1 (en) * 2016-11-10 2018-05-17 Janssen Pharmaceutica Nv Benzocyclobutane derivatives useful as dual sglt1/sglt2 modulators
CN108203432B (zh) * 2016-12-20 2021-03-02 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
AR111161A1 (es) 2017-03-03 2019-06-12 Novartis Ag Régimen de dosificación para el inhibidor sglt1/2 (licogliflozin)
WO2018189671A1 (en) * 2017-04-12 2018-10-18 Novartis Ag Use of lik066 in heart failure patients
US11179364B2 (en) 2017-06-21 2021-11-23 Novartis Ag Licofligozin for the treatment of non-alcoholic steatohepatitis
US10696662B2 (en) 2017-08-21 2020-06-30 Janssen Pharmaceutica Nv 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
GB201721967D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721961D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721960D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721957D0 (en) * 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721964D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
CN108863736A (zh) * 2018-07-27 2018-11-23 福州大学 一种羰基功能化的芳香羧酸的制备方法
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2020151623A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及其作为药物中间体的应用
WO2020151620A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及其作为药物中间体的应用
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
KR20220038368A (ko) 2019-07-23 2022-03-28 노파르티스 아게 Fxr 작용제를 이용하는 간 질환의 병용 치료
CN111099975A (zh) * 2019-12-23 2020-05-05 河北合佳医药科技集团股份有限公司 一种5-溴-2-氯-4’-乙氧基二苯甲酮的制备方法
EP4249479A4 (en) * 2020-11-19 2024-12-18 Beijing Increase Innovative Drug Co., Ltd. GLUCOSIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS APPLICATION
KR20220080880A (ko) * 2020-12-08 2022-06-15 주식회사 종근당 엠파글리플로진 공결정을 함유하는 약제학적 조성물
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
US5410031A (en) * 1992-02-24 1995-04-25 The Regents Of The University Of California Office Of Technology Transfer Nucleoside cotransporter protein cDNA
US5410054A (en) 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
AU6024998A (en) 1997-01-15 1998-08-07 Glycomed Incorporated Aryl c-glycoside compounds and sulfated esters thereof
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
JP4272319B2 (ja) * 1999-11-30 2009-06-03 アイシン精機株式会社 ヘッドレスト装置
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
ES2254376T3 (es) 2000-03-17 2006-06-16 Kissei Pharmaceutical Co., Ltd. Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados.
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6872706B2 (en) 2000-09-29 2005-03-29 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4590158B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
KR20050089156A (ko) 2002-12-04 2005-09-07 깃세이 야쿠힌 고교 가부시키가이샤 고혈당증에 기인하는 질환의 예방 또는 치료제
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
ATE419747T1 (de) 2003-02-05 2009-01-15 Hermann Koepsell Rs1 defizientes transgenes tier und dessen verwendungen
ES2567571T3 (es) 2003-03-14 2016-04-25 Astellas Pharma Inc. Derivados de C-glucósido y sales de los mismos
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
RS20060320A (sr) 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Supstituisani indazol-o-glukozidi
LT2896397T (lt) * 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
EP1660509B1 (de) 2003-08-26 2009-02-04 Boehringer Ingelheim International GmbH Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1724277A4 (en) 2004-03-04 2012-05-02 Kissei Pharmaceutical ACCOLE HETEROCYCLIC DERIVATIVE, DRUG-CONTAINING COMPOSITION THEREOF, AND THE USE THEREOF
AU2005219779B2 (en) 2004-03-04 2011-04-14 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1773800A1 (de) * 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006032693A1 (en) 2004-09-22 2006-03-30 Vib Vzw Intestinal epithelial glucose sensor
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1813611B1 (en) 2004-11-18 2014-10-01 Kissei Pharmaceutical Co., Ltd. 1-substituted-3- beta-d-glycopyranosylated nitrogenous hetero- cyclic compounds and medicines containing the same
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
JP5230613B2 (ja) * 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
WO2008115574A1 (en) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
TW200849035A (en) 2007-04-18 2008-12-16 Tethys Bioscience Inc Diabetes-related biomarkers and methods of use thereof
EP2197433A4 (en) 2007-08-20 2010-09-08 Sinai School Medicine REGULATION OF GLP-1 AND SGLT-1 IN GASTROINTESTINAL CELLS
MX2010002027A (es) 2007-08-23 2010-03-15 Theracos Inc Derivados de bencilbenceno y metodos de uso.
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
ES2541141T3 (es) * 2008-01-31 2015-07-16 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
WO2009143010A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyponatremia employing an sglt2 inhibitor and composition containing same
WO2009143021A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
WO2010031820A1 (en) 2008-09-19 2010-03-25 Novartis Ag Glucoside derivatives and uses thereof as sglt inhibitors
EA201100502A1 (ru) 2008-09-19 2011-10-31 Новартис Аг Гликозидные производные и их применения
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2010074219A1 (ja) 2008-12-26 2010-07-01 アステラス製薬株式会社 ベンゾチオフェン化合物
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
BRPI1008560B1 (pt) 2009-02-13 2021-08-31 Boehringer Ingelheim International Gmbh Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
AP2011005795A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof

Also Published As

Publication number Publication date
AU2010309833A1 (en) 2012-03-29
HK1168099A1 (zh) 2012-12-21
RS54563B1 (sr) 2016-06-30
CA2777812A1 (en) 2011-04-28
CN102656165A (zh) 2012-09-05
IL219309A (en) 2015-03-31
HUE027531T2 (en) 2016-10-28
US20120178680A1 (en) 2012-07-12
ECSP12011909A (es) 2012-07-31
US8466114B2 (en) 2013-06-18
CU20120062A7 (es) 2012-06-29
US20150141354A1 (en) 2015-05-21
UY32958A (es) 2011-05-31
JO3152B1 (ar) 2017-09-20
US20130017993A1 (en) 2013-01-17
EP2491029B1 (en) 2016-02-10
MA33737B1 (fr) 2012-11-01
PL2491029T3 (pl) 2016-07-29
US20140274921A1 (en) 2014-09-18
AU2010309833B2 (en) 2014-06-12
GT201200117A (es) 2013-09-23
BR112012009053B1 (pt) 2020-03-03
SG179562A1 (en) 2012-05-30
ES2564191T3 (es) 2016-03-18
CY1117409T1 (el) 2017-04-26
IL219309A0 (en) 2012-06-28
TN2012000109A1 (en) 2013-09-19
CR20120176A (es) 2012-05-22
TW201118104A (en) 2011-06-01
SI2491029T1 (sl) 2016-05-31
KR20120083484A (ko) 2012-07-25
TWI558723B (zh) 2016-11-21
US20110171159A1 (en) 2011-07-14
EA201200600A1 (ru) 2012-12-28
TWI594756B (zh) 2017-08-11
WO2011048112A1 (en) 2011-04-28
CU24079B1 (es) 2015-03-30
AR078685A1 (es) 2011-11-23
HN2012000798A (es) 2015-08-03
MY158326A (en) 2016-09-30
US20170042925A1 (en) 2017-02-16
TW201632190A (zh) 2016-09-16
USRE49080E1 (en) 2022-05-24
HRP20160436T1 (hr) 2016-05-20
PE20121281A1 (es) 2012-10-05
EA023781B1 (ru) 2016-07-29
PH12012500518A1 (en) 2016-05-20
ZA201201680B (en) 2012-11-28
JP2014040451A (ja) 2014-03-06
CO6531486A2 (es) 2012-09-28
JP2013508335A (ja) 2013-03-07
BR112012009053A2 (pt) 2016-04-19
CN102656165B (zh) 2015-02-11
KR20140054415A (ko) 2014-05-08
US9895389B2 (en) 2018-02-20
KR101465308B1 (ko) 2014-11-28
DK2491029T3 (en) 2016-04-11
CA2777812C (en) 2018-07-17
US8163704B2 (en) 2012-04-24
US8828951B2 (en) 2014-09-09
MX2012004700A (es) 2012-05-23
NZ598717A (en) 2014-04-30
EP2491029A1 (en) 2012-08-29
JP5384744B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
CL2012000991A1 (es) Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras.
CL2009001595A1 (es) Forma amorfa y cristalina de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetrahidro-2h-pirano-3,4,5-triol anhidro; composicion farmaceutica que comprende la forma cristalina, util para reducir la glucosa sanguinea, recuperar la sensibilidad a la insulina, tratar la diabetes tipo 2. obesidad.
CL2013002973A1 (es) Compuestos derivados de esteres de fenilglucopiranosil sustituidos mediadores del co-transportador sodio/d-glucosa (sglt); composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento del sindrome metabolico, sindrome x, diabetes, resistencia a la insulina, entre otros
DOP2011000058A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol utiles para usar como inhibidores del transportador de sodio-glucosa
PT2187742T (pt) Derivados de (2s,3r,4r,5s,6r)-2-(4-cloro-3-benzilfenil)-6-(hidroximetil)tetrahidro-2h-piran-3,4,5-triol para utilização no tratamento da diabetes
CL2008000192A1 (es) Compuestos derivados de purina sustituidos; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo a transplantes, leucemias, diabetes, entre otras.
EP4327867A3 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
BR112013028744A2 (pt) cocristais de ácido cítrico e de l-prolina de (2s,3r,4r,5s,6r)-2(3-((5-(4-fluorofenil)tiofen-2-il)metil)-4-metilfenil)-6-(hidroximetil)tetra-hidro-2h-piran-3,4,5-triol
WO2012165914A3 (en) Novel diphenylmethane derivatives as sglt2 inhibitors
AR084781A1 (es) Composiciones que comprenden y metodos que utilizan inhibidores de los cotransportadores de sodio-glucosa 1 y 2
MX2012002942A (es) Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
CL2011002835A1 (es) Compuestos derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para tratar dolores agudos o cronicos de tipos neurogeno, asociados a enfermedades inflamatorias, entre otros.
CL2008002111A1 (es) Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
MX2013014843A (es) Oxazepinas como moduladores del canal de iones.
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2009001203A1 (es) Compuestos derivados de indazol y pirazol sustituidos; composicion farmaceutica de dichos compuestos; kit farmaceutico; y su uso como activadores de la glucoquinasa para tratar enfermedades metabolicas tales como hiperglicemia, diabetes, dislipidemias, obesidad, sindrome metabolico x y enfermedades cardiovasculares.
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CL2008001197A1 (es) Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras.
CL2010001496A1 (es) Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina.
WO2012006014A3 (en) Multi-component pharmaceuticals for treating diabetes
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
BR112014010290B8 (pt) Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica
CL2011002041A1 (es) Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes.
PH12012502329A1 (en) Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof